Why surgery won the SYNTAX trial and why it matters.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27283748.
- Also identified by DOI 10.1016/j.jtcvs.2016.04.083.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) trial cause of death analysis shows that cardiac death due to myocardial infarction is 10 times higher with percutaneous coronary intervention than coronary artery bypass grafting in the higher-risk patients. There was a clear advantage for surgery in the prevention of death in both the intermediate and high SYNTAX score groups with 3-vessel disease and in the high SYNTAX score group with left main disease, and that incremental advantage is statistically significant and widening with time, which should be transparently communicated to patients.
Medical subject headings
- Coronary Artery Bypass
- Coronary Artery Disease
- Myocardial Infarction
- Percutaneous Coronary Intervention